Subscribe

Biocompounding

Biocompounding

3 Top Biotech News Of The Week (13 August 22)

3 Top Biotech News Of The Week (13 August 22)

1) Pfizer's acquisition of Global Blood Therapeutics The acquisitions continue! This week Pfizer reported that it will be acquiring Global Blood Therapeutics (GBT) for $5.4B. The proposed acquisition is expected to drive growth by bringing GBT's sickle cell disease (SCD) expertise together with a robust

3 Top Biotech News Of The Week (6 August 22)

3 Top Biotech News Of The Week (6 August 22)

1) Beam served with clinical hold for Beam-201 $BEAM announced an FDA clinical hold on Beam-201, its multiplex silenced CD7 CAR-T asset. Beam-201 is an ex-vivo T-cell therapy being developed for relapsed/refractory T-cell acute lymphoblastic leukemia (ALL) and T-cell lymphoblastic lymphoma.

3 Top Biotech News Of The Week (30 July 22)

3 Top Biotech News Of The Week (30 July 22)

On Wednesday, the Federal Reserve raised interest rates by 75 basis points, at the same time, however, stocks closed the week higher with S&P 500 posting the best month since 2020. The biotech sector on the other hand had a relatively flat week, with the $XBI index rising

A Deep Dive Into a Pioneer in CRISPR Gene Editing (CRISPR Therapeutics)

A Deep Dive Into a Pioneer in CRISPR Gene Editing (CRISPR Therapeutics)

What You Need to Know About Growth Investing & Two Potential Metrics to Use

What You Need to Know About Growth Investing & Two Potential Metrics to Use

There are different investing styles that individuals can adopt, and each has its own advantages and disadvantages. The most important thing for us to do is to pick an investing style that we feel most comfortable with. That’s how we can sleep soundly at night. The different investing styles

8 Gene Editing/CRISPR Companies to Consider For Your Portfolio

8 Gene Editing/CRISPR Companies to Consider For Your Portfolio

Ten years ago, Jennifer Doudna and her colleagues published the results of a test-tube experiment on bacterial genes in the journal "Science". This paper was the beginning of an adventurous journey that led to the development of CRISPR technology. In the past decade, CRISPR has become one

Thermo Fisher Scientific (TMO) a healthcare juggernaut you cannot ignore

Thermo Fisher Scientific (TMO) a healthcare juggernaut you cannot ignore

Thermo Fisher Scientific (NYSE: TMO) is a healthcare sector juggernaut that produces and supplies scientific instruments, reagents, consumables and offers contract services through its CDM and CRO businesses. With a galaxy of critical services and products, Thermo Fisher is a force to be reckoned with in healthcare. Two key competitive